An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus

被引：146

作者：

Patel, JB ^{[1
]}

Jevitt, LA ^{[1
]}

Hageman, J ^{[1
]}

McDonald, LC ^{[1
]}

Tenover, FC ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Div healthcare Qual Promot, Atlanta, GA 30333 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 11期

关键词：

D O I：

10.1086/504084

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1652 / 1653

页数：2

共 9 条

[1] Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].

Akins, RL ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459

[2] Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].

Carpenter, CF ;

Chambers, HF .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000

[3]

Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P322

[4] Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene [J].

Chang, S ;

Sievert, DM ;

Hageman, JC ;

Boulton, ML ;

Tenover, FC ;

Downes, FP ;

Shah, S ;

Rudrik, JT ;

Pupp, GR ;

Brown, WJ ;

Cardo, D ;

Fridkin, SK .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1342-1347

[5]

CLSI Manual Clinical and Laboratory Standards Institute, 2006, M100S16 CLSI

[6] Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus [J].

Cui, L ;

Ma, XX ;

Sato, K ;

Okuma, K ;

Tenover, FC ;

Mamizuka, EM ;

Gemmell, CG ;

Kim, MN ;

Ploy, MC ;

El Solh, N ;

Ferraz, V ;

Hiramatsu, K .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) :5-14

[7] Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50 [J].

Hanaki, H ;

Kuwahara-Arai, K ;

Boyle-Vavra, S ;

Daum, RS ;

Labischinski, H ;

Hiramatsu, K .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :199-209

[8] In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium [J].

Jevitt, LA ;

Smith, AJ ;

Williams, PP ;

Raney, PM ;

McGowan, JE ;

Tenover, FC .

MICROBIAL DRUG RESISTANCE, 2003, 9 (04) :389-393

[9] Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania [J].

Tenover, FC ;

Weigel, LM ;

Appelbaum, PC ;

McDougal, LK ;

Chaitram, J ;

McAllister, S ;

Clark, N ;

Killgore, G ;

O'Hara, CM ;

Jevitt, L ;

Patel, JB ;

Bozdogan, B .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :275-280

← 1 →